Isogenica enters collaborative agreement with University of Cambridge Professor

Isogenica Ltd today announced that it has entered into a collaborative agreement with Professor Sir Tom Blundell of the University of Cambridge.

The initial focus of the collaboration will involve the use of leading edge molecular modelling techniques to further optimise a novel peptide scaffold framework that has already demonstrated high affinity binding to targets and is amendable to chemical synthesis. The optimised scaffold will form the basis of a new library format which Isogenica will add to its existing libraries. This will then be offered as part of Isogenica's discovery service.

Kevin Matthews, CEO of Isogenica commented: "We are delighted to have the opportunity to work with Professor Sir Tom Blundell and his research team. As a company we are focused on servicing the protein engineering needs of the pharmaceutical and biotech industries. One element of this is to employ modelling tools to understand the structural space that is inhabited by the proteins we discover, and as a result, combine in-silico and in-vitro techniques to optimise lead candidate development for targeting protein-protein interactions in drug discovery. The peptide scaffold also offers opportunities for reagent development."

Source: Isogenica